最新研究证实,对患有非转移性尤因瘤(E-wing’s sarcoma,内皮细胞性骨髓瘤)的病人而言,在确诊时就将异环磷酰胺(ifosfamide,烷化剂抗肿瘤药)和抗肿瘤植物药表鬼臼毒吡喃葡萄糖苷(又称依托泊苷,鬼臼乙叉苷,etoposide)添加到标准的化学治疗方案中,可显著地提高患者的生存率。然而,由来自于美国马萨诸塞州波士顿哈佛医学院Dana-Farber癌症研究所和附属儿童医院的Holcombe E.Grier医生指导的一项多中心研究报道表明,该治疗方法或许并不会影响到转移性疾病患者的临床治疗结果。此前研究已证实,尤因瘤与骨骼的原始神经外胚层瘤(PNET,一种在儿童、青少年和年轻人中较 Recent research confirms that in patients with non-metastatic E-wing sarcoma, ifosfamide (alkylating agent antineoplastic) and Antineoplastic botanical drug podophyllotoxin (also known as etoposide, etoposide, etoposide) added to the standard chemotherapy regimen, can significantly improve patient survival. However, a multicenter study led by Holcombe E. Grier, MD, from the Dana-Farber Cancer Institute and a children’s hospital at Harvard Medical School in Boston, Massachusetts, showed that this treatment may or may not affect metastatic disease The patient’s clinical outcome. Earlier studies have shown that Ewing’s tumor is associated with the primitive neuroectodermal tumor of the skeleton (PNET, a disease that affects children, adolescents, and young adults